Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Articles
Articles
PIK3CA-Mutated Breast Cancer
Trial to Assess Alpelisib in Combination with Fulvestrant in PIK3CA-Mutated HR-Positive/HER2-Negative Advanced Breast Cancer
SABCS 2022
Clinical trial assessing the additive benefit of alpelisib to fulvestrant in treatment-refractory HR-positive/HER2-negative ABC currently enrolling patients.
Read More ›
PIK3CA-Mutated Breast Cancer
Assessing the Additive Benefit of Alpelisib to Fulvestrant in Advanced Breast Cancer Across the Gene Mutation Landscape: Findings from a Post Hoc Analysis of the SOLAR-1 Trial
SABCS 2022
Results from the SOLAR-1 study demonstrate that only PIK3CA mutations can predict sensitivity to alpelisib in patients with HR-positive/HER2-negative breast cancer.
Read More ›
PIK3CA-Mutated Breast Cancer
Long-Term Disease Control with Fulvestrant plus Alpelisib in PIK3CA-Mutated HR-Positive/HER2-Negative Advanced Breast Cancer: Findings from Cohort A of the BYLieve Study
SABCS 2022
Findings from Cohort A of the BYLieve study suggest that treatment of HR-positive/HER2-negative breast cancer with PIK3CA mutation drivers with alpelisib plus fulvestrant may lead to long-term disease control.
Read More ›
PIK3CA-Mutated Breast Cancer
Trial to Assess Alpelisib in Combination with Tucatinib in PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
SABCS 2022
Clinical trial assessing alpelisib plus tucatinib in HER2-positive mBC with PIK3CA mutations is currently enrolling patients.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Patient-Reported Outcomes and Progression-Free Survival Findings from the 5th Interim Analysis of the RIBANNA Trial in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer
SABCS 2022
Interim analysis of the RIBANNA trial demonstrates that ribociclib provides a meaningful PFS benefit and maintains QOL in patients with HR-positive/HER2-negative advanced breast cancer.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Pooled Analysis of Post-Progression Treatments after Ribociclib in the MONALEESA-2, -3, and -7 Trials in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer
SABCS 2022
Post-progression targeted therapy after ribociclib found to result in increased duration of therapy.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Ribociclib-Derived Resistance Mutations: ctDNA Findings from the MONALEESA-2, -3, and -7 Trials
SABCS 2022
Comprehensive analysis of acquired resistance mutations in patients with HR-positive/HER2-negative advanced breast cancer post-CDK4/6 inhibitor and endocrine therapy is the largest to date.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Pooled Analysis of Gene Expression and Associated Treatment Response in the MONALEESA-2, -3, and -7 Trials
SABCS 2022
Results from the MONALEESA trials show that PFS benefit with ribociclib in combination with endocrine therapy found to be consistent regardless of expression levels of most cell cycle genes.
Read More ›
HR-Positive/HER2-Negative Breast Cancer
Comparison of Progression-Free Survival from the MONALEESA and RIBANNA Trials in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer
SABCS 2022
Analysis from the MONALEESA and RIBANNA trials in patients with HR-positive/HER2-negative advanced breast cancer finds differences in PFS among patients treated with ribociclib in combination with endocrine therapy among MONALEESA-like subgroups.
Read More ›
Federal Legislative and Regulatory Landscape
Updates in Federal Healthcare Legislature and Regulatory Policy
AMCP Nexus 2022
An overview of recently passed legislation and proposals anticipated in the coming year
Read More ›
Page 22 of 147
19
20
21
22
23
24
25
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us